Navigation Links
Data from Randomized Pilot Study, Real-World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
Date:5/8/2008

Other Data Presentations to Focus on Use of Pro-Healing Stent with AMI

Patients and Those Who Cannot Tolerate Dual-Antiplatelet Therapy

HONG KONG, May 8 /PRNewswire/ -- Twelve-month follow-up data from both a randomized pilot study and the real-world registry use of OrbusNeich's Genous Bio-engineered R stent, the world's first pro-healing stent, will be presented next week in a symposium at EuroPCR 2008 in Barcelona, Spain.

The symposium, titled "Clinical Impact of the Pro-Healing Stent," will take place at noon on May 15. Germano Di Sciascio, M.D., professor and chairman of cardiology at Campus Biomedico, University of Rome, Italy, will serve as the chairperson of the symposium and will present 14 month follow up data on 78 patients treated with the Genous stent.

Jonathan Hill, M.D., of King's College, London, will discuss the functional importance of endothelial progenitor cells for accelerated natural healing. Huay-Cheem Tan, M.D., National University Hospital, Singapore will present on the use of the Genous Bio-engineered R stent in acute myocardial infarction patients and Michael Kutryk, M.D., Ph.D. of St. Michael's Hospital, Toronto will focus on the use of the stent in patients who cannot tolerate dual-antiplatelet therapy.

Robbert de Winter, M.D., Ph.D., director of the catheterization laboratory at the Academic Medical Center, Amsterdam, will show the 12 month follow-up data from a 193-patient, single-center, prospective, single blind study called TRIAS HR Pilot with the Genous stent randomized with a drug eluting stent. In addition, de Winter will include interim follow up data from patient subsets in e-HEALING, a monitored, multi-center, worldwide (outside the United States) prospective registry with 5,000 enrolled patients. Dr de Winter is the principal investigator of the TRIAS HR Pilot study and co-principal investigator of the e-HEALING registry.

"We expect the data to strengthen our conviction that Genous is a very important and promising alternative to drug-eluting stents," said de Winter. "EuroPCR is the ideal venue at which we can share our findings and demonstrate the impact that the Genous technology is having on the interventional cardiology community."

Unlike drug-eluting stents, Genous, which is coated with an antibody, captures a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process. EPCs circulate in the bloodstream and are involved in the repair of blood vessels. When attracted to the surface of Genous, EPCs rapidly form an endothelial layer over the stent that provides protection against thrombus and minimizes restenosis.

OrbusNeich designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. The company's product portfolio includes the Genous Bio-engineered R stent, an antibody-coated device that is the first-ever stent to capture a patient's endothelial progenitor cells (EPCs) to accelerate the natural healing process following placement. Other products are stents, balloons and guiding catheters marketed under the names of Blazer(TM), R stent(TM), Sapphire(TM), Avita(TM), Avita HP(TM), SafeCut(TM), Lumina(TM) and Saffron.

A global company, OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo; and Shenzhen, China. OrbusNeich, which has provided cardiology devices to physicians through its predecessor companies since 1979, today supplies products to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

Editor's Note: OrbusNeich will display the Genous Bio-engineered R stent at Booth No. F06 at EuroPCR 2008.


'/>"/>
SOURCE OrbusNeich
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Agennix Initiates A Randomized Double-Blind, Placebo-Controlled Phase 2 Study of Oral Talactoferrin in Severe Sepsis
2. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
3. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
4. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
5. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
6. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
7. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
8. MonoSol Rx Completes Thin Film Ondansetron Pilot Bioequivalence Study
9. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
(Date:10/11/2017)... PARK, Calif. , Oct. 11, 2017  BioPharmX ... national scientific team that developed an innovative way to ... quantity of the delivery of new drugs. ... 2017 Fall Clinical Dermatology Conference will show how researchers ... General Hospital, Harvard Medical School used a suite of ...
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... in the greater Dallas, Miami, and Raleigh regions, is organizing an extended charity ... a rare and deadly chromosome abnormality. , After struggling since birth with several ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family ... next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. ... 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming the ...
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Ellevate Network, the ... business to advocate for action towards gender equality at their inaugural Summit in New ... the globe, and reached a social audience of over 3 million. To watch the ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Software Development, has been awarded a contract by the Center for Medicare and ... aims to accelerate the enterprise use of Agile methodologies in a consistent and ...
Breaking Medicine News(10 mins):